Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001976408-23-000041 Act: 33 Size: 7 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002258 Act: 34 Size: 485 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002208 Act: 34 Size: 136 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-002170 Act: 34 Size: 52 KB 网页链接
$Sol-gel(SLGL)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001178913-23-001854 Act: 33 Size: 130 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-001851 Act: 34 Size: 118 KB 网页链接
$Sol-gel(SLGL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001316 Act: 33 Size: 1 KB 网页链接
$Sol-gel(SLGL)$ 144 Report of proposed sale of securities Accession Number: 0001975896-23-000001 Act: 33 Size: 6 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-23-001210 Act: 34 Size: 13 KB 网页链接
$Sol-gel(SLGL)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001178913-23-001062 Act: 34 Size: 57 KB 网页链接